ijms-logo

Journal Browser

Journal Browser

Molecular Mechanisms, Pathogenesis, and Novel Therapeutic Strategies in Cardiovascular Disease, 2nd Edition

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".

Deadline for manuscript submissions: 31 March 2026 | Viewed by 120

Special Issue Editor


E-Mail Website
Guest Editor
Division of Vascular Surgery, Department of Surgery, University of Wisconsin School of Medicine and Public Health, 1111 Highland Avenue, Madison, WI 53705, USA
Interests: aneurysm; vascular biology; angiogenesis; intimal hyperplasia; macrophage; osteoclastogenesis; MMPs
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Aneurysms, characterized by the localized dilation of blood vessels, pose a significant health risk due to the potential for rupture and life-threatening hemorrhage. In recent years, there has been growing interest in understanding the molecular mechanisms underlying the development and progression of aneurysms. This Special Issue aims to highlight recent advances in aneurysm research, focusing on the molecular aspects of aneurysm formation, progression, and novel therapeutic strategies.

In this Special Issue of the International Journal of Molecular Sciences, we invite authors to submit original research articles, reviews, and perspectives that delve into the molecular underpinnings of aneurysm formation and progression, specifically in relation to cardiovascular disease. Topics of interest include, but are not limited to, vascular remodeling, extracellular matrix degradation, the role of inflammatory signaling pathways, and the identification of novel molecular targets for therapy.

We particularly encourage submissions that provide in-depth insights into the molecular mechanisms of aneurysm pathobiology and the intricate interplay between various cellular and molecular factors contributing to aneurysm development. Contributions exploring innovative therapeutic approaches, such as gene therapy, stem cell therapy, and pharmacological interventions targeting specific molecular pathways, are also welcome.

By assembling a diverse collection of high-quality articles, this Special Issue aims to advance our understanding of the complex molecular landscape governing aneurysm formation and progression in cardiovascular disease and to inspire further research in this rapidly evolving field.

Dr. Dai Yamanouchi
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • aneurysm pathobiology
  • vascular remodeling
  • extracellular matrix degradation
  • inflammatory signaling pathways
  • molecular targets for therapy
  • autophagy
  • macrophage
  • inflammation
  • immune cell regulation
  • age-related diseases
  • therapeutic implications

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Related Special Issue

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

16 pages, 304 KB  
Review
The Roles of Incretin Hormones GIP and GLP-1 in Metabolic and Cardiovascular Health: A Comprehensive Review
by Dai Yamanouchi
Int. J. Mol. Sci. 2026, 27(1), 27; https://doi.org/10.3390/ijms27010027 - 19 Dec 2025
Abstract
The incretin hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) play central roles in metabolic and cardiovascular regulation. GLP-1 receptor agonists (GLP-1RAs) are established therapies for type 2 diabetes mellitus (T2DM) and obesity because of their insulinotropic effects, weight reduction, and proven [...] Read more.
The incretin hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) play central roles in metabolic and cardiovascular regulation. GLP-1 receptor agonists (GLP-1RAs) are established therapies for type 2 diabetes mellitus (T2DM) and obesity because of their insulinotropic effects, weight reduction, and proven cardiovascular benefit in trial level. In contrast, GIP was historically overlooked due to reduced β-cell responsiveness in T2DM. The development of dual GIP/GLP-1 receptor agonists has reshaped this view. Tirzepatide, the first-in-class co-agonist, an antidiabetic medication to treat type 2 diabetes and for weight loss, provides superior glycemic control and weight loss compared with selective GLP-1RAs in clinical trials, demonstrating synergistic actions between the two incretin pathways. This review summarizes key physiology, pathophysiology, and therapeutic evidence in incretin biology. We describe secretion patterns, receptor distributions, and distinct actions of GIP and GLP-1, as well as alterations in incretin signaling in T2DM and obesity. Cardiovascular protective mechanisms are outlined, including improvements in lipid metabolism, reductions in blood pressure, enhanced endothelial nitric oxide activity, suppression of macrophage inflammation, decreased foam-cell formation, and stabilization of atherosclerotic plaques. At the therapeutic level, emerging directions—such as dual and triple agonists—and unresolved questions regarding long-term vascular effects of GIP and the potential for genotype-guided incretin therapy are also discussed. Collectively, these findings highlight an emerging shift toward integrated incretin-axis modulation as a therapeutic strategy for metabolic and cardiovascular disease. Full article
Show Figures

Graphical abstract

Back to TopTop